The market value of "Innovative Medicine One Brother" has its limit lower and the market value of 27 exclusive Chinese patent medicines will be collected. Kelun, Beite...781 medicines are "not playing anymore"

This week, the news of centralized procurement is coming.

Started in September, the country of insulin is here

On August 18, the industry issued the "National Organization of Insulin Centralized Purchase Plan (Draft for Comment)".

Focus

Purchasing scope and grouping: The second-generation and third-generation insulins are divided into 3 groups according to quick-acting, basic and pre-mixing, and a total of 6 groups

Winning rules: if many wins, increase the winning rate appropriately

Allocation rules: report by label next year demand; reference Kayaku States adopt rules, quotes from low to high Class A (low offer), C class (the last one selected), the other for class B

74 Chinese patent medicines to be collected

On August 17, a letter entitled "Hubei Provincial Medical Security Bureau on Inviting Participation in the Centralized Procurement of Proprietary Chinese Patent Medicine Provincial Cross-regional Alliance" was circulated in the industry

View

In recent years, the demand for national procurement of Chinese patent medicines and granular formulations has been increasing.

Implementation of the fifth batch of centralized procurement

On August 17, Heilongjiang, Hainan, Xinjiang, and Liaoning issued a document to implement the results of the fifth batch of centralized procurement.

781 drugs "no longer play"

On August 18, the Heilongjiang Province Drug Centralized Procurement Network issued a notice.

Well-known pharmaceutical company was sold

On August 18, Shanxi Zhendong Pharmaceutical issued an announcement to sell 100% of its wholly-owned subsidiary Langdi Pharmaceuticals to Shanghai Fanglang for 5.

Further reading

Langdi Pharmaceuticals is the "cash cow" of Zhendong Pharmaceutical.

640 million dollars! CSPC innovative drugs successfully "going overseas"

On August 17, CSPC announced that its subsidiary NovaRock and Flame Biosciences have reached a cooperation of up to US$640 million

Data theory

NBL-015 is a fully human anti-Claudin 18.

The most expensive new stock! Yiqiao Shenzhou earns 150,000 yuan in the first lottery

On August 16, Yiqiao Shenzhou, known as "the most expensive new stock of A shares", successfully landed on the ChiNext of the Shenzhen Stock Exchange.

Further reading

In addition to attracting attention due to the high issue price, Yiqiao Shenzhou is still a "anti-epidemic" concept stock

Innovative drugs sold over 5 billion! Hengrui's first large-scale public R&D pipeline

On August 19, Hengrui Medicine released the first half of 2021 performance report

Further reading

Or because the performance of the semi-annual report was lower than market expectations, Hengrui Medicine dropped its limit shortly after the opening on August 20.
As of the close, it was reported at 48.
46 yuan per share, with the latest market value of 310 billion yuan
.
Compared with the highest share price in January this year at 97.
22 yuan per share, Hengrui Medicine's share price has been cut in half
.

New drug "King of Childhood Tumors" was born

On August 18, BeiGene announced that the National Food and Drug Administration has approved the listing of dartuximab β, becoming the first domestic targeted immunotherapy drug for the treatment of neuroblastoma
.
Datuximab β is a disialoganglioside (GD2) monoclonal antibody developed by EUSA Pharma.
It is the first drug approved by the FDA to treat high-risk neuroblastoma in children
.
Due to the high degree of malignancy, rapid progression of the disease and the treatment is difficult, neuroblastoma is often called the "king of childhood cancer"
.
(Medicine time)

34 drugs actively cut prices

On August 16-18, the Guangzhou Public Resources Trading Center issued a notice of voluntary price reductions for some drugs.
After an enterprise's voluntary application, the transaction prices of 34 drugs (in terms of serial numbers) were adjusted, including Nanjing Zhengda Tianqing’s injection of Iraqi hydrochloride.
of doxorubicin, Qilu propofol tenofovir fumarate tablets, Sanofi Elixiyou monoclonal antibody injection, ex China midazolam injection solution or the like
.
(Guangzhou Public Resources Trading Center)

Changes in senior management of many well-known pharmaceutical companies

On August 18, Huadong Medicine announced that Mr.
Li Yuedong, the company’s director and general manager, had resigned due to physical reasons
.
Yunnan Baiyao announced that the company’s directors, Mr.
Wang Rong and Mr.
Na Pengjie, resigned due to personal or work reasons
.
Huaheng Biotech announced that Mr.
Shi Yunzhong, director of the company, resigned due to personal work reasons; on August 17, Ganli Pharmaceutical announced that the company’s director Ms.
Wang Damei and supervisor Mr.
Yang Jinhui resigned due to personal reasons
.
Ji Pharmaceutical Holdings announced that Mr.
Gu Yunzhe, director of the company, resigned due to personal reasons
.
Hisun Pharmaceutical announced that Mr.
Li Siqi, the company's senior vice president, resigned due to personal reasons
.
Baiyunshan announced that the company's executive deputy general manager Wu Changhai and deputy general manager Zhang Chunbo resigned due to job transfer
.
(Announcement of listed companies)

Multinational pharmaceutical company disbanded retail chronic disease sales team

Recently, it has been reported that Huizhi, a well-known multinational pharmaceutical company, is disbanding its chronic disease sales team in the retail market.
The last working day of its team is September 17
.
It is reported that the compensation plan for this negotiation is (N+1) * average monthly salary + 2 * basic salary.
In addition, a long-term savings plan of 10% of the basic salary per month can also be withdrawn
.
The retail chronic disease representatives of Huizhi South China and Eastern China will gradually merge into the retail product team, and the North China retail chronic disease team will be basically disbanded
.
(Pharmaceutical Administration)